loader
Please Wait
Applying Filters...

AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X

Technical details about Zotatifin, learn more about the structure, uses, toxicity, action, side effects and more

Client Email Product
Menu
2D Structure
1. Also known as: 2098191-53-6, Eft226, Eft-226, Zotatifin [inn], Zotatifin [usan], 2ewn8z05cn
Molecular Formula
C28H29N3O5
Molecular Weight
487.5  g/mol
InChI Key
QYCXWOACFWMQFO-WZWZCULESA-N
FDA UNII
2EWN8Z05CN

Zotatifin is a selective inhibitor of the eukaryotic translation initiation factor 4A (eIF4A), with potential antineoplastic activity. Upon administration of zotatifin, this agent targets and binds to elF4A, and promotes eIF4A binding to mRNA with specific polypurine motifs within their 5'-untranslated region (5'-UTR), leading to the formation of a stable sequence-specific ternary complex with eIF4A and mRNA (elF4A- zotatifin-mRNA). This results in the translational repression of key oncogenes and anti-apoptotic proteins involved in tumor cell proliferation, survival and metastasis, such as KRAS, Myc, myeloid cell leukemia-1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), cyclin-dependent kinase (CDK) 4 and 6, cyclin D, fibroblast growth factor receptor (FGFR) 1 and 2, human epidermal growth factor receptor 2 (HER2; ERBB2), and beta-catenin. The inhibition of the expression of these oncogenes leads to the inhibition of various oncogenic signal transduction pathways. This inhibits proliferation and induces apoptosis in tumor cells. eIF4A, a RNA helicase and the rate-limiting component of the eukaryotic translation initiation complex, catalyzes the ATP-dependent unwinding of RNA duplexes and facilitates 43S ribosome scanning within the 5'-UTR. elF4A is activated by various oncogenic signaling pathways, including RAS/mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)/AKT pathways, and regulates the translation of oncogenes and tumor survival factors with complex secondary structures within the 5'-UTRs that are required for tumor cell proliferation, survival and metastasis.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[(2S,3R,4S,5S,6R)-4-[(dimethylamino)methyl]-2,3-dihydroxy-10,12-dimethoxy-5-phenyl-7-oxa-11-azatricyclo[6.4.0.02,6]dodeca-1(12),8,10-trien-6-yl]benzonitrile
2.1.2 InChI
InChI=1S/C28H29N3O5/c1-31(2)16-20-23(18-8-6-5-7-9-18)28(19-12-10-17(15-29)11-13-19)27(33,25(20)32)24-21(36-28)14-22(34-3)30-26(24)35-4/h5-14,20,23,25,32-33H,16H2,1-4H3/t20-,23-,25-,27+,28+/m1/s1
2.1.3 InChI Key
QYCXWOACFWMQFO-WZWZCULESA-N
2.1.4 Canonical SMILES
CN(C)CC1C(C2(C(C1O)(C3=C(N=C(C=C3O2)OC)OC)O)C4=CC=C(C=C4)C#N)C5=CC=CC=C5
2.1.5 Isomeric SMILES
CN(C)C[C@@H]1[C@H]([C@]2([C@@]([C@@H]1O)(C3=C(N=C(C=C3O2)OC)OC)O)C4=CC=C(C=C4)C#N)C5=CC=CC=C5
2.2 Other Identifiers
2.2.1 UNII
2EWN8Z05CN
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 2098191-53-6

2. Eft226

3. Eft-226

4. Zotatifin [inn]

5. Zotatifin [usan]

6. 2ewn8z05cn

7. 4-((5ar,6s,7s,8r,8as)-7-((dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5ah-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl)benzonitrile

8. 4-((5ar,6s,7s,8r,8as)-7-((dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5ah-cyclopenta(4,5)furo(3,2-c)pyridin-5a-yl)benzonitrile

9. Benzonitrile, 4-((5ar,6s,7s,8r,8as)-7-((dimethylamino)methyl)-6,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5ah-cyclopenta(4,5)furo(3,2-c)pyridin-5a-yl)-

10. Zotafin

11. Rel-zotatifin

12. Zotatifin (usan/inn)

13. Unii-2ewn8z05cn

14. Zotatifin [who-dd]

15. Chembl4303782

16. Schembl18864788

17. Dtxsid001022536

18. Ex-a4623

19. Bdbm50540861

20. Nsc818001

21. Nsc828584

22. Who 10998

23. Nsc-818001

24. Nsc-828584

25. Hy-112163

26. Cs-0043584

27. D11837

28. A937238

29. 4-[(2s,3r,4s,5s,6r)-4-[(dimethylamino)methyl]-2,3-dihydroxy-10,12-dimethoxy-5-phenyl-7-oxa-11-azatricyclo[6.4.0.02,6]dodeca-1(12),8,10-trien-6-yl]benzonitrile

2.4 Create Date
2017-08-04
3 Chemical and Physical Properties
Molecular Weight 487.5 g/mol
Molecular Formula C28H29N3O5
XLogP32.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count6
Exact Mass487.21072103 g/mol
Monoisotopic Mass487.21072103 g/mol
Topological Polar Surface Area108 Ų
Heavy Atom Count36
Formal Charge0
Complexity819
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Post Enquiry
POST ENQUIRY